CENERX NEWS & EVENTS

12-JAN-10

New Clinical Study Shows Anxiolytic Potential of CeNeRx’s Novel Mechanism HPA Axis Modulator Compounds.

Hypothalamic-Pituitary-Adrenal (HPA) Axis Modulator CXB722 Demonstrates Promising Activity in Trier Social Stress Test;
Positive Study Results Confirm Distinctive Mechanism of Action and Set the Stage for Further Clinical Development of CXB722 Prodrug Ayrene
Read more...

07-DEC-09

Publication in Neuropsychopharmacology Confirms CeNeRx’s Novel RIMA Antidepressant TriRima™ Selectively and Reversibly Inhibits MAO-A.
Innovative PET Imaging Studies Confirm TriRima™ Demonstrates Reversible Inhibition of MAO-A in the Human Brain;
Represents First Validation in Humans of Mechanism of RIMA Antidepressants
Read more..

16-JUN-09

CeNeRx Biopharma Completes $9 Million Financing.

New Funds to Support Advancement of Multiple Novel Programs for CNS Disorders

Read more...

16-JUN-09

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders.
Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically
Broad Potential Applications Include Neuropathies, Alzheimer’s and Huntingdon’s Disease and Others
Read more..

1-APR-09

CeNeRx BioPharma Awarded New Patent for Its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors.

By Avoiding the CNS, These Compounds May Be Free of the Side Effects Associated with Traditional Cannabinoid Compounds

.
Read more...

12-FEB-09

CeNeRx Biopharma Reports Robust Patient Enrollment in Phase II Trial of Its Novel Antidepressant Agent TriRima™.
Rapid Enrollment of Targeted Patients Seen as an Indicator of High Unmet Need for Improved Therapeutic Options in this Patient Group.
Read more..

17-OCT-08

CeNeRx BioPharma Completes $15 Million Series B Financincing.

New Funds Will Support Phase II Trial of Novel Antidepressant Tyrima™ and Advancement of Cannabinoid Compounds.

Read more...

17-OCT-08

CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima™.
Read more...

22-JUL-08

CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima™.
State-of-the-Art PET Study Confirms Tyrima Exhibits Excellent Drug-Like Properties. Results Support Initiation of Phase II Clinical Trials
Read more...

12-MAY-08

CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development.
Former GSK Clinical Development Head Brings Over 20 Years of Clinical and Product Development Expertise to the Company’s CNS Portfolio
Read more...

16-JAN-08

CeNeRx BioPharma Announces Successful Completion of Phase I Clinical Program for Novel Antidepressant Agent Tyrima™
Tyrima Exhibits Excellent Safety Profile and Favorable Pharmacokinetics in Phase I Studies
Read more...